within Pharmacolibrary.Drugs.ATC.G;

model G03FA16
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0003,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600,            
    Vdp             = 0.1,
    k12             = 20,
    k21             = 20
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03FA16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trimegestone and estrogen (ATC code G03FA16) is a combination oral contraceptive containing a progestogen (trimegestone) and an estrogen (usually estradiol). It is used for hormonal contraception, treatment of menopausal symptoms, and hormone replacement therapy. As of the current date, this specific fixed combination is not widely approved or available in all markets.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data specifically for the fixed combination of trimegestone and estrogen (G03FA16). Parameter values are estimated based on typical PK properties of trimegestone and estradiol in adult women.</p><h4>References</h4><ol><li><p>Bray, JD, et al., &amp; Lyttle, CR (2005). Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. <i>The Journal of steroid biochemistry and molecular biology</i> 97(4) 328–341. DOI:<a href=&quot;https://doi.org/10.1016/j.jsbmb.2005.06.032&quot;>10.1016/j.jsbmb.2005.06.032</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16157482/&quot;>https://pubmed.ncbi.nlm.nih.gov/16157482</a></p></li><li><p>Pettersen, PC, et al., &amp; Christiansen, C (2008). Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms. <i>Climacteric : the journal of the International Menopause Society</i> 11(2) 135–143. DOI:<a href=&quot;https://doi.org/10.1080/13697130801930385&quot;>10.1080/13697130801930385</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18365856/&quot;>https://pubmed.ncbi.nlm.nih.gov/18365856</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03FA16;
